Molecular characterization of commonly used cell lines for bone tumor research: A trans-European EuroBoNet effort

Genes Chromosomes and Cancer

Volumn 49, Issue 1, 2010, Pages 40-51

  Ottaviano, Laura ^a   Schaefer, Karl Ludwig ^a   Gajewski, Melanie ^a   Huckenbeck, Wolfgang ^a   Baldus, Stefan ^a   Rogel, Uwe ^a   Mackintosh, Carlos ^b   De Alava, Enrique ^b   Myklebost, Ola ^c   Kresse, Stine H ^c   Meza Zepeda, Leonardo A ^c   Serra, Massimo ^d   Cleton Jansen, Anne Marie ^e   Hogendoorn, Pancras C W ^e   Buerger, Horst ^f   Aigner, Thomas ^g   Gabbert, Helmut E ^a   Poremba, Christopher ^a,h  

^a University Medical Center Duesseldorf   (Germany)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h Research Park Trier   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CANCER CELL CULTURE; CANCER LOCALIZATION; CANCER RESEARCH; CHILD; CHONDROSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FINGERPRINTING; EWING SARCOMA; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE LOSS; GENETIC SCREENING; HEALTH CARE ORGANIZATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MISSENSE MUTATION; MOLECULAR CLONING; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEUROECTODERM TUMOR; NONSENSE MUTATION; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOMEDICAL RESEARCH; BONE NEOPLASMS; CELL LINE, TUMOR; COOPERATIVE BEHAVIOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EUROPE; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

MAMMALIA;

EID: 74949090294     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20717     Document Type: Article

References (49)

1. Alldinger I, Schaefer KL, Goedde D, Ottaviano L, Dirksen U, Ranft A, Juergens H, Gabbert HE, Knoefel WT, Poremba C. 2007. Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression. J Cancer Res Clin Oncol 133:749-759.
2. Benini S, Baldini N, Manara MC, Chano T, Serra M, Rizzi S, Lollini PL, Picci P, Scotlandi K. 1999. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 80:581-588.
3. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF. 1992. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749.
4. Bourdon JC. 2007. p53 and its isoforms in cancer. Br J Cancer 97:277-282.
5. Brownhill SC, Taylor C, Burchill SA. 2007. Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br J Cancer 96:1914-1923.
6. Bruland OS, Fodstad O, Stenwig AE, Pihl A. 1988. Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. Cancer Res 48:5302-5309.
7. Chandar N, Billig B, McMaster J, Novak J. 1992. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 65:208-214.
8. DeAlava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindán FJ, Healey JH, Ladanyi M. 2000. Prognostic impact of P53 status in Ewing sarcoma. Cancer 89:783-792.
9. Domagk D, Schaefer KL, Eisenacher M, Braun Y, Wai DH, Schleicher C, Diallo-Danebrock R, Bojar H, Roeder G, Gabbert HE, Domschke W, Poremba C. 2007. Expression analysis of pancreatic cancer cell lines reveals association of enhanced gene transcription and genomic amplifications at the 8q22.1 and 8q24.22 loci. Oncol Rep 17:399-407.
10. Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Scott CE, Smith J, Vetrie D, Gorman P, Tomlinson IP, Carter NP. 2003. DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer 36:361-374. Erratum in: Genes Chromosomes Cancer 37:223.
11. Friedrichs N, Kriegl L, Poremba C, Schaefer KL, Gabbert HE, Shimomura A, Paggen E, Merkelbach-Bruse S, Buettner R. 2006. Pitfalls in the detection of t(11;22) translocation by fluorescence in situ hybridization and RT-PCR: A single-blinded study. Diagn Mol Pathol 15:83-89.
12. Fodstad O, Brøgger A, Bruland O, Solheim OP, Nesland JM, Pihl A. 1986. Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma. Int J Cancer 38:33-40.
13. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. 2005. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122.
14. Gil-Benso R, Lopez-Gines C, López-Guerrero JA, Carda C, Callaghan RC, Navarro S, Ferrer J, Pellín A, Llombart-Bosch A. 2003. Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879: Comparative histologic and genetic studies with its tumor of origin. Lab Invest 83:877-887.
15. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. 2001. Cancer statistics. CA Cancer J Clin 51:15-36.
16. Hall PA, McCluggage WG. 2006. Assessing p53 in clinical contexts: Unlearned lessons and new perspectives. J Pathol 208:1-6.
17. Helman LJ, Meltzer P. 2003. Mechanisms of sarcoma development. Nat Rev Cancer 3:685-694.
18. Henriksen J, Aagesen T, Maelandsmo GM, Lothe RA, Myklebost O, Forus A. 2003. Amplification and overexpression of COPS3potentially target TP53 for proteasome-mediated degradation. Oncogene 22:5358-5361.
19. Hensler PJ, Annab LA, Barrett JC, Pereira-Smith OM. 1994. A gene involved in control of human cellular senescence on human chromosome 1q. Mol Cell Biol 14:2291-2297.
20. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M. 2005. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: A highly lethal subset associated with poor chemoresponse. J Clin Oncol 23:548-558.
21. Honoki K, Stojanovski E, McEvoy M, Fujii H, Tsujiuchi T, Kido A, Takakura Y, Attia J. 2007. Prognostic significance of p16 INK4a alteration for Ewing sarcoma: A meta-analysis. Cancer 110:1351-1360.
22. Jagasia AA, Block JA, Qureshi A, Diaz MO, Nobori T, Gitelis S, Iyer AP. 1996. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. Cancer Lett 105:91-103.
23. Kjønniksen I, Winderen M, Bruland O, Fodstad O. 1994. Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. Cancer Res 54:1715-1719.
24. Knijnenburg J, Szuhai K, Giltay J, Molenaar L, Sloos W, Poot M, Tanke HJ, Rosenberg C. 2005. Insights from genomic microarrays into structural chromosome rearrangements. Am J Med Genet A 132A:36-40.
25. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, Salzer-Kuntschik M, Gadner H. 1993. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 8:2683-2690.
26. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B, Windhager R, Gadner H. 1997. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15:2225-2232.
27. Maitra A, Roberts H, Weinberg AG, Geradts J. 2001. Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. Int J Cancer 95:34-38.
28. Meinhold-Heerlein I, Ninci E, Ikenberg H, Brandstetter T, Ihling C, Schwenk I, Straub A, Schmitt B, Bettendorf H, Iggo R, Bauknecht T. 2001. Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 60:176-188.
29. Momand J, Jung D, Wilczynski S, Niland J. 1998. The MDM2 gene amplification database. Nucleic Acids Res 26:3453-3459.
30. Nelson-Rees WA, Daniels DW, Flandermeyer RR. 1981. Cross-contamination of cells in culture. Science 212:446-452.
31. Ouyang P. 1998. An in vitro model to study mesenchymal-epithelial transformation. Biochem Biophys Res Commun 246:771-776.
32. Pakos EE, Kyzas PA, Ioannidis JP. 2004. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: A meta-analysis. Clin Cancer Res 10:6208-6214.
33. Pelotti S, Ceccardi S, Alu' M, Lugaresi F, Trane R, Falconi M, Bini C, Cicognani. 2007. Cancerous tissues in forensic genetic analysis. Genet Test 11:397-400.
34. Peter M, Couturier J, Pacquement H, Michon J, Thomas G, Magdelenat H, Delattre O. 1997. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 14:1159-1164.
35. Rhim JS, Putman DL, Arnstein P, Huebner RJ, McAllister RM. 1977. Characterization of human cells transformed in vitro by N-methyl-N'-nitro-N-nitrosoguanidine. Int J Cancer 19:505-510.
36. Sandberg AA, Bridge JA. 2003. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and relatcd tumors. Cancer Genet Cytogenet 145:1-30.
37. Savola S, Nardi F, Scotlandi K, Picci P, Knuutila S. 2007. Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma. Cytogenet Genome Res 119:21-26.
38. Schaefer KL, Wai D, Poremba C, Diallo R, Boecker W, Dockhorn-Dworniczak B. 2002. Analysis of TP53 germline mutations in pediatric tumor patients using DNA microarray-based sequencing technology. Med Pediatr Oncol 38:247-253.
39. Schaefer KL, Eisenacher M, Braun Y, Brachwitz K, Wai DH, Dirksen U, Lanvers-Kaminsky C, Juergens H, Herrero D, Stegmaier S, Koscielniak E, Eggert A, Nathrath M, Gosheger G, Schneider DT, Bury C, Diallo-Danebrock R, Ottaviano L, Gabbert HE, Poremba C. 2008. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 44:699-709.
40. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. 2002. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57.
41. Schulz A, Battmann A, Heinrichs CM, Kern A, Tiedemann A, Bürger H, Fohr B, Hani N, Pietruck C, Busk H, Jundt G. 1993. Properties and reactivity of a new human osteosarcoma cell line (HOS 58). Calcif Tissue Int 52:30.
42. Skubitz KM, D'Adamo DR. 2007. Sarcoma. Mayo Clin Proc 82:1409-1432.
43. Ternovoi VV, Curiel DT, Smith BF, Siegal GP. 2006. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab Invest 86:748-766.
44. Urano F, Umezawa A, Yabe H, Hong W, Yoshida K, Fujinaga K, Hata J. 1998. Molecular analysis of Ewing's sarcoma: Another fusion gene, EWS-E1AF, available for diagnosis. Jpn J Cancer Res 7:703-711.
45. vanden Berg H, Kroon HM, Slaar A, Hogendoorn PCW. 2008. Incidence of biopsy-proven bone tumors in children: A report based on the Dutch pathology registration "PALGA." J Pediatr Orthop 28:29-35.
46. van Valen F. 1998. Ewing's sarcoma family of tumors. In: Masters JR, Palsson B, editors. Human Cell Culture, Vol. 1. London: Kluwer Academic Publisher, pp. 55-85.
47. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310.
48. Wang H, Huang S, Shou J, Su EW, Onyia JE, Liao B, Li S. 2006. Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling data. BMC Genomics 7:166.
49. Wunder JS, Gokgoz N, Parkes R, Bull SB, Eskandarian S, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Malkin D, Mangham DC, Rock MJ, Bell RS, Andrulis IL. 2005. TP53 mutations and outcome in osteosarcoma: A prospective, multicenter study. J Clin Oncol 23:1483-1490.